Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - moxifloxacin - film-coated tablet - 400 milligram(s) - fluoroquinolones; moxifloxacin

Singapura - Inggeris - HSA (Health Sciences Authority)

teva pharmaceutical investments singapore pte. ltd. - moxifloxacin hcl 436.37 mg eqv moxifloxacin - tablet, film coated - moxifloxacin hcl 436.37 mg eqv moxifloxacin 400 mg

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - danofloxacin - solution for injection - 180 mg/ml - bovine - antibacterial

Ireland - Inggeris - HPRA (Health Products Regulatory Authority)

schering plough limited - orbifloxacin, micronised - oral suspension - 30 mg/ml - canine - antibacterial

Sepanyol - Inggeris - HMA (Heads of Medicines Agencies)

pfizer limited - danofloxacin mesilate 180 mg/ml - solution for injection - cattle - danofloxacine

Perancis - Inggeris - HMA (Heads of Medicines Agencies)

pfizer limited - danofloxacin mesilate 180 mg/ml - solution for injection - cattle - danofloxacine

Malta - Inggeris - HMA (Heads of Medicines Agencies)

pfizer limited - danofloxacin mesilate 180 mg/ml - solution for injection - cattle - danofloxacine

Romania - Inggeris - HMA (Heads of Medicines Agencies)

pfizer limited - danofloxacin mesilate 180 mg/ml - solution for injection - cattle - danofloxacine

Israel - Inggeris - Ministry of Health

bayer israel ltd - moxifloxacin as hydrochloride - film coated tablets - moxifloxacin as hydrochloride 0.4 g - moxifloxacin - moxifloxacin - for the treatment of the following bacterial infections in patients of 18 years and older• respiratory infections : - uncomplicated acute bacterial sinusitis (abs) - acute exacerbations of chronic bronchitis (aecb) megaxin tablets should be used to treat adequately diagnosed abs and aecb only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections or when these have failed to resolve the infection. - community acquired pneumonia, except severe cases. megaxin tablets should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of this infection. • community-acquired spontaneous and wound infections of the skin and skin structure.appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with megaxin tablets may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.consideration should be given to official guidance on the appropriate use of antibacterial agents.

Israel - Inggeris - Ministry of Health

bayer israel ltd - moxifloxacin as hydrochloride - film coated tablets - moxifloxacin as hydrochloride 0.4 g - moxifloxacin - moxifloxacin - for the treatment of the following bacterial infections in patients of 18 years and older• respiratory infections : - uncomplicated acute bacterial sinusitis (abs) - acute exacerbations of chronic bronchitis (aecb) megaxin tablets should be used to treat adequately diagnosed abs and aecb only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections or when these have failed to resolve the infection. - community acquired pneumonia, except severe cases. megaxin tablets should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of this infection. • community-acquired spontaneous and wound infections of the skin and skin structure.appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with megaxin tablets may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.consideration should be given to official guidance on the appropriate use of antibacterial agents.